Huvepharma Announces FDA-Approval for Cattle Feed Additive, Optigrid® 45 (Ractopamine Hydrochloride Type A Medicated Article)
PEACHTREE CITY, GA (May 19, 2020) — Global animal health company, Huvepharma®, has received FDA-approval for Optigrid® 45, a feed additive used to promote weight gain and improve feed efficiency in finishing feedlot cattle.
Optigrid® 45, which is comprised of the active ingredient ractopamine hydrochloride, is a bio-equivalent product to Optaflexx®. It can be fed as a complete feed or top dress feed to cattle fed in confinement for slaughter during the last 28 to 48 days on feed prior to harvest. When fed as a complete feed, ractopamine hydrochloride can also promote increased carcass leanness.
“In today’s challenging world, with the continued need for efficiency in beef production, we are pleased to bring further medicated feed additive options such as Optigrid® 45 to the cattle industry,” says Glen Wilkinson, president of Huvepharma, Inc. (U.S.).
Wilkinson points out that as an FDA-approved bio-equivalent, Optigrid® 45 provides the same benefits of dosage, chemical identity, potency, quality and safety to the existing ractopamine hydrochloride brand.
“Optigrid® 45 adds another choice from Huvepharma’s expanding product line and is a continued example of our commitment to bring our core strength in medicated feed additives to the U.S. animal food producing industry,” adds Wilkinson. “Huvepharma’s product development, regulatory and sales teams are dedicated to providing effective and essential animal health products to the livestock industry.”
Huvepharma received FDA approval for Monovet® 90 (monensin Type A medicated article) – a bio-equivalent to Rumensin – in July 2019, and has offered animal health products for poultry, swine and cattle in the U.S. since 2005.
Throughout the U.S., Huvepharma is focused on building partnerships with industry customers by offering high quality products and unparalleled customer service. For more information, please contact your Huvepharma sales representative and/or Huvepharma’s Customer Service team at 877-994-4883 or visit www.huvepharma.us.
Huvepharma is a global pharmaceutical company with a focus on developing, manufacturing and marketing human and animal health products. A privately-owned company headquartered in Sofia, Bulgaria, Huvepharma’s U.S. headquarter are located in Peachtree City, GA. Learn more about Huvepharma and its products at https://huvepharma.us/.
Huvepharma is a registered trademark of Huvepharma EOOD.
Optaflexx and Rumensin are registered trademarks of Elanco U.S. Inc.